Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
Location: United States, California, San Carlos
Employees: 51-200
Founded date: 2013
Investors 7
Date | Name | Website |
- | BioRock Ve... | biorockven... |
- | Foresite C... | foresiteca... |
- | RA Capital... | racap.com |
- | Frazier Li... | frazierls.... |
01.10.2021 | Abingworth... | abingworth... |
- | Longitude ... | longitudec... |
- | CARB-X | carb-x.org |
Mentions in press and media 8
Date | Title | Description | Source |
19.04.2023 | Vaxcyte Announces Pricing of $500 Million Public Offering | - | globenewsw... |
26.10.2022 | Vaxcyte Announces Pricing of $600 Million Public Offering | SAN CARLOS, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage... | globenewsw... |
13.01.2022 | Vaxcyte Announces Pricing of $100 Million Public Offering | SAN CARLOS, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innova... | marketscre... |
13.01.2022 | Vaxcyte Announces Pricing of $100 Million Public Offering | SAN CARLOS, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innova... | globenewsw... |
25.03.2021 | Moncef Slaoui is retreating from the biotech industry after ... | Moncef Slaoui, the former chief advisor to the White House’s Operation Warp Speed vaccine initiative... | businessin... |
23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know: – Healthcare venture capital firm Longitude Capital announces the close of its... | hitconsult... |
23.09.2020 | Longitude Capital Raises $585 Million Fund to Invest in Tran... | - Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, en... | marketscre... |
- | GSK fires ex-Operation Warp Speed chief Moncef Slaoui over ‘... | Moncef Slaoui was fired as Galvani Bioelectronics board chairman over “substantiated” allegations of... | cnbc.com/2... |